Inclusion Criteria:

- Histologically proven NSCLC diagnosis

- Life expectancy over four weeks

- absolute neutrophil count ≥ 2.0X109/L, Pt ≥ 100X109/L, hemoglobin ≥ 90g/l

- With normal hepatic function(AST, ALT < 2.5 x upper limit of normal , and Total
bilirubin ≤ upper limit of normal)

- Suitable for EGFR-TKIs treatment and expectant duration over four weeks

- No specific therapies received within 4 weeks prior to enrollment which may induce
similar skin reaction,such as Cetuximab, Sorafenib, Avastin.

- With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity
Criteria for Adverse Events [NCI-CTC] grade ≥ 3)

- No other concomitant therapy referred to the face skin during the study

- Signed and dated informed consent

Exclusion Criteria:

- Performance status ≥ 3(ECOG)

- Pregnant or breast-feeding patients

- The lesion counts can't be evaluated due to concomitant diseases or other conditions

- Not suitable for EGFR-TKIs treatment